

PATENT/Docket No. PC27098
Appl. No. 10/687,986
Filing Date: October 17, 2003
Response to Restriction Requirement of February 7, 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1654
Examiner : Gudibande, Satyanarayan R.
Applicant(s) : Nancy Jean Britten
Serial Number : 10/687,986
Filed : October 17, 2003
Confirmation No. : 1367
Docket No. : PC27098
For : DISPERSIBLE PHARMACEUTICAL COMPOSITIONS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

Claims 1-48 are pending in the present application. The claims have been subject to a restriction/election of species requirement. Applicants elect the Group I claims, that is, claims 1-40. In response to the election of species requirement Applicants elect ceftiofur hydrochloride as the antibacterial substance. Applicants also elect Labrafil M-19944CS, which is a polyglycolized glyceride having oleic acid as the main fatty acid component, as the amphipathic oil, and cottonseed oil as the non-aqueous carrier. In response to the election of species requirement Applicants elect, with traverse, the mammary gland as the single organ. Applicants respectfully suggest that since pharmaceutical composition claims 1-40 have been elected for prosecution, an election of species requirement relating only to claims which have been withdrawn under the restriction requirement is inappropriate.

PATENT/Docket No. PC27098

Appl. No. 10/687,986

Filing Date: October 17, 2003

Response to Restriction Requirement of February 7, 2008

If the Examiner believes that personal communications will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

Dated: FEB 28, 2008

John H. Engelmann

John H. Engelmann

Registration No. 28,075

Pfizer Inc.

7000 Portage Road

Kalamazoo, MI 49001

Tel. (269) 833-2532

Fax (269) 833-8897